
1 anthracycline (a) v non-anthracycline (b) (OR)
Feher 2005 1.49 (0.91, 2.42)
Hernadi 1988a 4.63 (0.24, 90.41)
Martin 2003 5.13 (1.64, 16.02)
Sweetnam 1986 8.82 (2.87, 27.12)
Subtotal (I-squared = 72.0%, p = 0.013) 2.27 (1.50, 3.43)
.
2 anthracycline (a) v mitoxantrone (b) (OR)
Cavo 2002 1.52 (0.54, 4.26)
Pavlovsky 1992 1.02 (0.20, 5.32)
Stewart 1997 0.95 (0.06, 15.21)
Subtotal (I-squared = 0.0%, p = 0.898) 1.31 (0.57, 3.03)
.
4 epirubicin (a) v doxorubicin (b) (OR)
Bezwoda 1986 0.14 (0.01, 1.41)
FESG, 1988 0.08 (0.02, 0.37)
Gasparini 1991 0.13 (0.00, 6.51)
IMBSWE, 1988 0.53 (0.33, 0.84)
Jain 1995 1.14 (0.30, 4.39)
Lawton 1993b 1.00 (0.06, 16.40)
Subtotal (I-squared = 43.2%, p = 0.117) 0.47 (0.31, 0.71)
5 liposomal doxorubicin (a) v doxorubicin (b) (RR)
Batist 2001 0.30 (0.15, 0.60)
Harris 2002 0.44 (0.25, 0.78)
O'Brien 2004 0.21 (0.11, 0.40)
Subtotal (I-squared = 32.2%, p = 0.229) 0.30 (0.21, 0.43)
.
6 liposomal doxorubicin (a) v epirubicin (b) (RR)
Chan, 2004 1.15 (0.47, 2.84)
Subtotal (I-squared = .%, p = .) 1.15 (0.47, 2.84)
.
7 cardioprotective agent (a) v none (b) (RR)
Marty, 2006 0.32 (0.17, 0.62)
Speyer, 1992 0.16 (0.07, 0.35)
Swain, 1997 0.46 (0.33, 0.66)
Venturini, 1996 0.32 (0.13, 0.76)
Wexler 1996 0.25 (0.11, 0.55)
Subtotal (I-squared = 44.2%, p = 0.127) 0.34 (0.27, 0.45)
.
.01 .1 .2 1 5 10 100
Favours a Favours b